Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases

References

• Egeler RM, D'Angio GJ. Langerhans cell histiocytosis. J Pediatr 1995;127:1–11.
   PubMed Web of Science ®Google Scholar
• Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999;33: 476–81.
   PubMedGoogle Scholar
• Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis – evolution and current approaches. Br J Cancer Suppl 1994;23:S41–6.
   PubMedGoogle Scholar
• Satter EK, High WA. Langerhans cell histiocytosis: A review of the current recommendations of the Histiocyte Society. Pediatr Dermatol 2008;25:291–5.
   PubMed Web of Science ®Google Scholar
• Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 1997;28:9–14.
   PubMedGoogle Scholar
• Aricò M, Girschikofsky M, Généreau T, Klersy C, McClain K, Grois N, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:2341–8.
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol 2006;76:363–8.
   PubMed Web of Science ®Google Scholar
• McClain K, Allen C, Ebrahim S. Review of histiocytosis treatment and neurotoxicity in adult patients (abstract). Pediatr Blood Cancer 2009;53:696.
   Web of Science ®Google Scholar
• Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728–9.
   PubMed Web of Science ®Google Scholar
• Histiocyte Society Evaluation and Treatment Guidelines. Available from: http://www.hematologie-amc.nl/odijk/bijlagennietinDBS/SocietyLCHTreatmentGuidelines.pdf.[cited 2012 April 3]
   Google Scholar
• Kassner E. Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 2000;17:135–48.
   PubMed Web of Science ®Google Scholar
• Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2- Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 1993;329:734–5.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma 1997;25:187–9.
   PubMed Web of Science ®Google Scholar
• Weitzman S, Braier J, Donadieu J, Egeler RM, Grois N, Ladisch S, et al. 2’-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S 98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009;53:1271–6.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood 1999;93:4125–30.
   PubMed Web of Science ®Google Scholar
• Grau J, Ribera JM, Tormo M, Indiano JM, Vercher J, Sandoval V, et al. Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients. Med Clin (Barc) 2001;116:339–42. [Spanish].
   PubMed Web of Science ®Google Scholar
• Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003;78:301–6.
   PubMed Web of Science ®Google Scholar
• Stine KC, Saylors RL, Williams LL, Becton DL. 2- Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997;29:288–92.
   PubMedGoogle Scholar
• Szturz P, Adam Z, Rehák Z, Koukalová R, Slaisová R, Stehlíková O, et al. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol 2012;51: 412–5.
   PubMed Web of Science ®Google Scholar
• Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest 1990;86:1480–8.
   PubMed Web of Science ®Google Scholar
• Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997;32:120–31.
   PubMed Web of Science ®Google Scholar
• Bryson HM, Sorkin EM. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993;46:872–94.
   PubMed Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2’- deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 1992;10:1514–8.
   PubMed Web of Science ®Google Scholar
• Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Engl J Med 2004;351:1034–5.
   PubMed Web of Science ®Google Scholar
• Baumann M, Cerny T, Sommacal A, Koeberle D. Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. Hematol Oncol 2012;30:101–4.
   PubMed Web of Science ®Google Scholar
• Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J Sci Am 1998;4(Suppl 2):S27–36.
   PubMedGoogle Scholar
• Robak T, Kordek R, Robak E, Bartkowiak J, Biernat W, Liberski P, et al. Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: A clonal disease responding to treatment with cladribine, and cyclophosphamide. Leuk Lymph 2002;43:2041–6.
   PubMed Web of Science ®Google Scholar
• Felix CA. Chemotherapy-related second cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia (PA): Lippincott Williams and Wilkins; 1999.
   Google Scholar
• Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: A case report of reversibility with 2- chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003;25: 575–7.
   PubMed Web of Science ®Google Scholar